Vaxart Inc
NASDAQ:VXRT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Vaxart Inc
Short-Term Investments
Vaxart Inc
Short-Term Investments Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Short-Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Vaxart Inc
NASDAQ:VXRT
|
Short-Term Investments
$14.1m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
1%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Short-Term Investments
$28m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
13%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Short-Term Investments
$68m
|
CAGR 3-Years
-59%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
-28%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Short-Term Investments
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Short-Term Investments
$1.5B
|
CAGR 3-Years
77%
|
CAGR 5-Years
18%
|
CAGR 10-Years
17%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Short-Term Investments
$5.5B
|
CAGR 3-Years
6%
|
CAGR 5-Years
32%
|
CAGR 10-Years
37%
|
|
Vaxart Inc
Glance View
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. The company is headquartered in South San Francisco, California and currently employs 110 full-time employees. Its programs include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). The Company’s product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. The firm is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus.
See Also
What is Vaxart Inc's Short-Term Investments?
Short-Term Investments
14.1m
USD
Based on the financial report for Dec 31, 2025, Vaxart Inc's Short-Term Investments amounts to 14.1m USD.
What is Vaxart Inc's Short-Term Investments growth rate?
Short-Term Investments CAGR 10Y
1%
Over the last year, the Short-Term Investments growth was -47%. The average annual Short-Term Investments growth rates for Vaxart Inc have been -34% over the past three years , and 1% over the past ten years .
